Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Zydus-Lifesciences-Ltd"

43 News Found

Zydus launches Sitaglyn and Siglyn for the management of Type 2 diabetes
News | July 10, 2022

Zydus launches Sitaglyn and Siglyn for the management of Type 2 diabetes

The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes

Zydus receives final approval from USFDA for Lacosamide injection
Drug Approval | July 01, 2022

Zydus receives final approval from USFDA for Lacosamide injection

Lacosamide Injection is used to treat partial-onset seizures.

Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel
Drug Approval | June 07, 2022

Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel

The drug will be manufactured at the group’s topical facility at Ahmedabad

Latest Stories

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging